Search | Clinical Trials Finder

Conditions: HIV-1 Infection
Interventions: B/F/TAF, NRTIs, Third Agent; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 82
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more

Conditions: HIV, HIV Infections
Interventions: E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more

Conditions: HIV Infected
Interventions: Tenofovir, Emtricitabine, Atazanavir, Ritonavir; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 40 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Human Immunodeficiency Virus
Interventions: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV), tenofovir/emtricitabine (TDF/FTC), Atazanavir (ATV), Ritonavir, Phlebotomy; Drug · Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections
Interventions: Raltegravir and truvada, Atazanavir, Norvir and Truvada; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV-1 Infection
Interventions: E/C/F/TAF, E/C/F/TDF, ATV, RTV, FTC/TDF, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 29
States / cities: Stamford, Connecticut • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 22 more

Conditions: Healthy
Interventions: tenofovir, emtricitabine, atazanavir, ritonavir; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: HIV
Interventions: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir; Drug
Lead sponsor: Kenneth H. Mayer, MD; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir, Tenofovir/emtricitabine FDC; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 37
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more

Conditions: Healthy Volunteer
Interventions: atazanavir, danoprevir, ritonavir, tenofovir disoproxil fumarate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: HIV-1 Infection
Interventions: E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more

Conditions: HIV-1 Infection
Interventions: Nuvaring, EFV, ATV/r, TDF, NRTIs; Device · Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 16 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more

Conditions: HIV-DDI
Interventions: Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Orlando, Florida • Boston, Massachusetts

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: PI, RTV, FTC/TDF, Stribild; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 45
States / cities: Phoenix, Arizona • Beverly Hills, California • Hayward, California + 28 more

Conditions: HIV Infections
Interventions: Atazanavir/Ritonavir, Atazanavir/Ritonavir + Famotidine, Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Voorhees Township, New Jersey • Chapel Hill, North Carolina • Philadelphia, Pennsylvania

Conditions: HIV-1 Infection
Interventions: COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 31
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 23 more

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TDF, PI, RTV, NRTIs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 66
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more

Conditions: HIV, HIV Infections
Interventions: COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 64
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more

Conditions: HIV Infections
Interventions: atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 1,578 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2020
U.S. locations: 39
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more

Conditions: HIV Infections
Interventions: ritonavir-boosted atazanavir, ritonavir-boosted fosamprenavir; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Atazanavir, Didanosine, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine, Lopinavir/Ritonavir, Nevirapine, Stavudine, Tenofovir disoproxil fumarate, Zidovudine/Lamivudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 3,526 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Atazanavir, Darunavir, Efavirenz, Nevirapine, Ritonavir, Tenofovir disoproxil fumarate, Pharmacokinetic Study; Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 17 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 21
States / cities: Alhambra, California • La Jolla, California • Long Beach, California + 16 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg, BMS-663068 1200 mg, Raltegravir 400 mg, Tenofovir 300 mg, Ritonavir 100 mg, Atazanavir 300 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 13
States / cities: San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more

Conditions: HIV Infections
Interventions: ATV, RTV, Tenofovi-Emtricitabine (TDF/FTC) tablet, LPV; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 8
States / cities: Phoenix, Arizona • Laguna Beach, California • Washington D.C., District of Columbia + 5 more

Search by objective public record fields.

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

Interaction With HIV Antiretroviral Agents

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

"The Once A Day Protease Inhibitor Regimens"

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada